Presented at ECCMID, Amsterdam, April 2019
Onufrak NJ, Rubino CM, Ambrose PG, Isaacs R, Srinivasan S and O'Donnell J (ECCMID 2019)
Program(s): durlobactam (etx2514)
Srinivasan S (ECCMID 2019))
Program(s): durlobactam (etx2514)
Efficacy of Cefpodoxime Proxetil and ETX0282 in a Murine UTI Model with E. coli and K. pneumoniae
Weiss WJ, Carter K, Pulse ME, Nguyen P, Valtierra D, Peterson K, Tommasi R, Mueller JP, O'Donnell J (ECCMID 2019)
Program(s): etx0282
Durand-Reville T (ECCMID 2019)
McLeod S, Moussa S, Huband M, Mueller J, Tommasi R and Miller A (ECCMID 2019)
Program(s): etx0282
McLeod S, Moussa S, Hackel M, Tommasi R and Miller A (ECCMID 2019)
Program(s): durlobactam (etx2514)
Seifert H, Stefanik, D, Muller C, Higgins P, Kresken M and Miller A (ECCMID 2019)
Program(s): durlobactam (etx2514)
Presented at ID Week, San Francisco, October 2018
ETX2514SUL (Sulbactam/ETX2514) for The Treatment of Acinetobacter baumannii Infection
Isaacs R (IDWeek 2018)
Program(s): durlobactam (etx2514)
Presented at ASM Microbe, Atlanta, GA, June 2018
Addressing the Challenge of Gram-negative Permeation in Antibacterial Discovery
Thomas Durand-Reville, ASM Microbe 2018
Sarah McLeod, ASM Microbe 2018
Program(s): durlobactam (etx2514)
John O'Donnell, ASM Microbe 2018
Program(s): durlobactam (etx2514)
Sarah McLeod, ASM Microbe 2018
Program(s): etx0282
Plasma and Intrapulmonary Concentrations of ETX2514 and Sulbactam in Healthy Adult Subjects
K.A. Rodvold (University of Illinois at Chicago), ASM Microbe 2018
Program(s): durlobactam (etx2514)